Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy

Annals of the Rheumatic Diseases

Volumn 75, Issue 10, 2016, Pages 1848-1851

  Van Der Valk, Fleur M ^a   Bernelot Moens, Sophie J ^a   Verweij, Simone L ^a   Strang, Aart C ^a   Nederveen, Aart J ^a   Verberne, Hein J ^a   Nurmohamed, Michael T ^b   Baeten, Dominique L ^a   Stroes, Erik S G ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ankylosing Spondylitis; Atherosclerosis; Cardiovascular Disease; Inflammation; Treatment

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ANKYLOSING SPONDYLITIS; ARTERY WALL; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENDER; HUMAN; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VASCULITIS; BLOOD; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; COMPLICATION; DRUG EFFECTS; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ATORVASTATIN CALCIUM; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84964727062     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209176     Document Type: Article

References (23)

1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127-37.
2. Exarchou S, Lie E, Lindström U, et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis 2016;75:1466-72.
3. Haroon NN, Paterson JM, Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 2015;163:409-16.
4. Libby P. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
5. Rose S, Sheth NH, Baker JF, et al. A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study. Am J Cardiovasc Dis 2013;3:273-8.
6. Tarkin JM, Joshi FR, Rudd JHF. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 2014;11:443-57.
7. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-31.
8. Ishii H, Nishio M, Takahashi H, et al. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled. Clin Ther 2010;32:2337-47.
9. Wu YW, Kao HL, Huang CL, et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging 2012;39:399-407.
10. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
11. Timár O, Szekanecz Z, Kerekes G, et al. Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis-a prospective case-series study. Arthritis Res Ther 2013;15:R105.
12. van Denderen JC, Peters MJL, van Halm VP, et al. Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:695-6.
13. Rollefstad S, Ikdahl E, Hisdal J, et al. Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study. Arthritis Rheumatol 2015;67:1718-28.
14. Ikdahl E, Hisdal J, Rollefstad S, et al. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther 2015;17:279.
15. Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
16. Heslinga SC, Van den Oever IA, Van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord 2015;16:80.
17. Figueroa AL, Abdelbaky A, Truong QA, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging 2013;6:1250-9.
18. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
19. Hamdi W, Chelli Bouaziz M, Zouch I, et al. Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2012;39:322-6.
20. Mäki-Petäjä KM, Elkhawad M, Cheriyan J, et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012;126:2473-80.
21. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818-24.
22. Tawakol A, Fayad ZA, Mogg R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multi-center FDG-PET/CT feasibility study. J Am Coll Cardiol 2013;62:909-17.
23. van Wijk DF, Sjouke B, Figueroa A, et al. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol 2014;64:1418-26.